A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Study identification

NCT ID

NCT06161571

Recruitment status

Active, not recruiting

Study type

Interventional

Phase

Phase 3

Lead sponsor

Akero Therapeutics, Inc

Industry

Enrollment

700 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years to 80 Years

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Nov 10, 2023 (Actual)

Primary completion

Mar 3, 2026 (Actual)

Completion

Jun 19, 2026 (Estimated)

Last update posted

Apr 30, 2026

2023 – 2026

United States locations

U.S. sites

139

U.S. states

28

U.S. cities

120

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 72 non-U.S. sites.